Saturday, November 21, 2026

ImmunoGen Stock Bearish By 10% So Far Today

Automated market report from our archive (2020-2024), published before source-traceability. How we work

ImmunoGen Stock Bearish By 10% So Far Today

ImmunoGen (IMGN) shares experienced an unanticipated drop of 10.887% to $2.20 during early trading periods on Monday, contrasting the NASDAQ's overall decline of 0.13%. This significant fall represented a substantial deviation from the company's positive performance observed throughout last week's trading sessions.

Current Performance Relative to Historical Highs and Lows

Despite closing the day around 17.54 percent lower than its 52-week high ($3.69), ImmunoGen has managed to comfortably stay above its 52-week low of $0.61.

About ImmunoGen

Based in Waltham, Massachusetts, ImmunoGen focuses on the development and commercialization of antibody-drug conjugates (ADCs) used in cancer therapy. Their primary products include mirvetuximab soravtansine, which treats platinum-resistant ovarian cancer, and Pivekimab sunirine which is in Phase II clinical trials for specific blood and lung cancer cases.

Financial Performance

ImmunoGen's portfolio appears promising. However, their financial reports show a net loss, even though their trailing twelve-month earnings per share (EPS) stand at 0.93. Their return on equity (ROE) - a key financial performance indicator over a one year period - is particularly concerning at -111.95%.

Sales Growth

For this quarter, ImmunoGen has recorded a sales growth of 241.4% and expects an additional increase of 339.8% for the next quarter.

Stock Volatility

ImmunoGen's current value and moving averages demonstrate persistent stock volatility. In the wake of the recent price dip, share prices are still below the 50-day moving average of $3.34 but have stayed above the 200-day moving average of $2.32. This suggests a short-term downswing without completely skewing towards a long-term bearish air.

Investor Advisory

Investors may want to keep a close eye on this stock given the contrast between its robust sales growth projections and the financial performance issues suggested by its negative return on equity.

More news about ImmunoGen (IMGN).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 7 Aug 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.